Gold prices slip lower; consolidating after recent gains
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) reported fourth-quarter earnings and revenue that exceeded analyst expectations, sending shares up 3.6% in after-hours trading.
The nutritional ingredient company posted adjusted earnings per share of $0.09 for the quarter, beating the consensus estimate of $0.02. Revenue came in at $29.1 million, surpassing analyst projections of $26.78 million and representing a 37% increase YoY.
ChromaDex’s strong performance was driven by growth in its Tru Niagen supplement brand, which saw sales rise 29% YoY to $22.7 million. The company also benefited from an 82% jump in Niagen ingredient sales for the full year.
"ChromaDex proudly delivered record breaking $29.1 million in net sales for the fourth quarter of 2024, up 37% from the prior year quarter, with $7.2 million in net income," said CEO Rob Fried.
Gross margin improved to 62.5% in Q4, up from 61% in the year-ago period. The company ended the year with $44.7 million in cash and no debt.
For 2025, ChromaDex expects approximately 18% YoY revenue growth, driven by e-commerce expansion, partnerships, and increased pharmaceutical-grade Niagen sales. The company anticipates slightly improved gross margins and stable marketing expenses as a percentage of sales.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.